NRIX Key Statistics, Chart & Performance
The current stock price of NRIX is 16.71 USD. In the past month the price decreased by -13.42%. In the past year, price decreased by -5%.
NRIX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NRIX. When comparing the yearly performance of all stocks, NRIX is one of the better performing stocks in the market, outperforming 70.28% of all stocks.
NRIX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NRIX. No worries on liquidiy or solvency for NRIX as it has an excellent financial health rating, but there are worries on the profitability.
NRIX Financial Highlights
Over the last trailing twelve months NRIX reported a non-GAAP Earnings per Share(EPS) of -3.04. The EPS decreased by -5.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.43% | ||
| ROE | -49.09% | ||
| Debt/Equity | 0 |
NRIX Forecast & Estimates
23 analysts have analysed NRIX and the average price target is 30.6 USD. This implies a price increase of 83.12% is expected in the next year compared to the current price of 16.71.
For the next year, analysts expect an EPS growth of -3.74% and a revenue growth -30.57% for NRIX
NRIX Ownership
NRIX Latest News, Press Relases and Analysis
NRIX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.37 | 394.886B | ||
| AMGN | AMGEN INC | 16.68 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.01 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.1 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.8 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.77 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 12.74 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.62 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NRIX
Company Profile
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Brisbane California, California and currently employs 317 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The firm is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.
Company Info
NURIX THERAPEUTICS INC
1600 Sierra Point Pkwy
Brisbane California CALIFORNIA 94158 US
CEO: Arthur T. Sands
Employees: 286
Phone: 14156605320
NURIX THERAPEUTICS INC / NRIX FAQ
What does NURIX THERAPEUTICS INC do?
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Brisbane California, California and currently employs 317 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The firm is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.
What is the stock price of NURIX THERAPEUTICS INC today?
The current stock price of NRIX is 16.71 USD. The price decreased by -0.83% in the last trading session.
Does NRIX stock pay dividends?
NRIX does not pay a dividend.
How is the ChartMill rating for NURIX THERAPEUTICS INC?
NRIX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of NURIX THERAPEUTICS INC (NRIX)?
NURIX THERAPEUTICS INC (NRIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.04).
Should I buy NRIX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NRIX.
Can you provide the upcoming earnings date for NURIX THERAPEUTICS INC?
NURIX THERAPEUTICS INC (NRIX) will report earnings on 2026-04-06.